FDA Limits Authorized Use Of Johnson & Johnson Coronavirus Vaccine Due To ‘Potentially Life-Threatening Blood Clots’

The U.S. Food and Drug Administration (FDA) announced late Thursday afternoon that it has limited the authorized use of the Johnson & Johnson vaccine to adults who cannot receive other coronavirus vaccines.

The FDA said in a statement, “After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine.”

The FDA said that the potential benefits for the vaccine outweighed its potential risks “for individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and for individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.”- READ MORE